Results 141 to 150 of about 3,549 (185)

Unraveling the Crimson puzzle: Two case reports/case series of hemorrhagic cystitis after combination chemotherapy with docetaxel, carboplatin, trastuzumab and pertuzumab in breast cancer. [PDF]

Medicine (Baltimore)
Ramirez JC, Lacey ME, Gowda MS, Wang G, Chamorro Y, Sandoval-Leon AC.   +5 more
europepmc   +1 more source

Differential impact of pegfilgrastim, a recombinant human granulocyte colony stimulating factor, on the neutrophil count of male and female deer mice (Peromyscus maniculatus bairdii). [PDF]

BMC Pharmacol Toxicol
Strydom JP, Brand L, Viljoen FP, Wolmarans W.   +3 more
europepmc   +1 more source

Optimal Primary Prophylaxis for Febrile Neutropenia During Neoadjuvant Cisplatin and 5-Fluorouracil Plus Docetaxel for Esophageal Cancer: A Retrospective Cohort Study. [PDF]

Cancer Med
Kumanishi R, Taniguchi H, Nakazawa T, Ogata T, Matsubara Y, Kodama H, Nakata A, Honda K, Masuishi T, Narita Y, Kadowaki S, Ando M, Tajika M, Abe T, Muro K.   +14 more
europepmc   +1 more source

Demonstration of physicochemical and functional similarity between Stimufend (pegfilgrastim-fpgk) and Neulasta (pegfilgrastim): A comparative analytical assessment. [PDF]

PLoS One
Sykes A, Ingram L, Kronthaler U, Chevalet L.   +3 more
europepmc   +1 more source

Safety and Efficacy of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Pegfilgrastim in Japanese Patients with Advanced or Metastatic Urothelial Carcinoma.

Chemotherapy
Harano T, Ikeda M, Hirano S, Shimura S, Toyoda M, Okuda S, Koguchi D, Tsumura H, Ishii D, Matsumoto K.   +9 more
europepmc   +1 more source

EMA approvals of new medicinal products and new biosimilar products in January and February 2025. [PDF]

Lancet Reg Health Eur
Burgos JG, Thirstrup S.
europepmc   +1 more source

Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings. [PDF]

BioDrugs
Kvien TK, Betteridge N, Brückmann I, Bodenmüller W, Bryn G, Danese S, Gonçalves J, Maravic Z, Thorne C, Wingate L, Cornes P.   +10 more
europepmc   +1 more source

Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia

Annals of Oncology, 2011
Background To study the effects of deferring pegfilgrastim until day 4 on the reduction of chemotherapy-induced leukocytopenia. Patients and methods Patients of age 61–80 years with aggressive lymphoma were randomly assigned to receive 6 mg ...
G Schlimok, M Loeffler
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Pegfilgrastim

Expert Opinion on Biological Therapy, 2002
Granulocyte colony stimulating factor (G-CSF) has proven efficacy in the prophylaxis of chemotherapy induced neutropenia and is associated with a reduction in the duration of neutropenia, febrile neutropenia, hospitalisation and intravenous antibiotic use.
Fenella, Willis, Ruth, Pettengell
  +6 more sources